Marshall Wace LLP Has $17.11 Million Holdings in BioNTech SE (NASDAQ:BNTX)

Marshall Wace LLP grew its holdings in BioNTech SE (NASDAQ:BNTX - Free Report) by 32.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 150,157 shares of the company's stock after purchasing an additional 37,177 shares during the period. Marshall Wace LLP owned about 0.06% of BioNTech worth $17,108,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in BNTX. FMR LLC increased its position in BioNTech by 22.2% in the 4th quarter. FMR LLC now owns 7,701,476 shares of the company's stock worth $877,583,000 after purchasing an additional 1,401,547 shares during the last quarter. abrdn plc raised its position in BioNTech by 70.7% during the fourth quarter. abrdn plc now owns 385,668 shares of the company's stock valued at $43,947,000 after acquiring an additional 159,676 shares in the last quarter. Franklin Resources Inc. lifted its stake in BioNTech by 3,942.1% in the fourth quarter. Franklin Resources Inc. now owns 136,786 shares of the company's stock valued at $15,587,000 after acquiring an additional 133,402 shares during the last quarter. CenterBook Partners LP grew its position in BioNTech by 62.5% in the fourth quarter. CenterBook Partners LP now owns 194,118 shares of the company's stock worth $22,120,000 after acquiring an additional 74,656 shares in the last quarter. Finally, Bank Julius Baer & Co. Ltd Zurich bought a new position in shares of BioNTech during the 4th quarter valued at $7,128,000. 15.52% of the stock is owned by hedge funds and other institutional investors.

BioNTech Stock Performance

BNTX traded down $18.52 during trading on Friday, reaching $102.02. 6,438,309 shares of the company's stock were exchanged, compared to its average volume of 897,110. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The business has a 50 day moving average price of $101.72 and a 200 day moving average price of $110.64. BioNTech SE has a fifty-two week low of $76.53 and a fifty-two week high of $131.49. The company has a market capitalization of $24.48 billion, a P/E ratio of -48.58 and a beta of 1.07.

BioNTech (NASDAQ:BNTX - Get Free Report) last announced its quarterly earnings results on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, beating analysts' consensus estimates of $0.38 by $0.70. The firm had revenue of $1.19 billion for the quarter, compared to analysts' expectations of $1.24 billion. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business's revenue was down 19.5% compared to the same quarter last year. During the same period in the prior year, the business posted $1.90 earnings per share. As a group, analysts predict that BioNTech SE will post -3.88 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on BNTX. Citigroup initiated coverage on shares of BioNTech in a report on Thursday, March 13th. They issued a "buy" rating and a $145.00 price objective for the company. BMO Capital Markets raised their price objective on BioNTech from $130.00 to $143.00 and gave the company an "outperform" rating in a research note on Tuesday, March 11th. HC Wainwright decreased their target price on BioNTech from $150.00 to $145.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. Canaccord Genuity Group reissued a "buy" rating and issued a $171.44 price target on shares of BioNTech in a research report on Tuesday, March 11th. Finally, Morgan Stanley reduced their price objective on shares of BioNTech from $145.00 to $139.00 and set an "overweight" rating for the company in a research note on Tuesday, March 11th. Three research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, BioNTech currently has a consensus rating of "Moderate Buy" and an average target price of $143.44.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.